Ralista 60, containing raloxifene, is primarily used to treat and prevent osteoporosis in postmenopausal women. However, studies suggest that it also plays a role in reducing the risk of hormone receptor-positive breast cancer. Raloxifene works as a selective estrogen receptor modulator (SERM), meaning it blocks estrogen’s effects on breast tissue while still benefiting bone health. Since estrogen can fuel the growth of certain breast cancers, Ralista 60 helps lower the risk of developing invasive breast cancer in women at high risk.

While Ralista 60 shows promise in breast cancer prevention, it is not a substitute for traditional treatments like chemotherapy or radiation for existing cancer cases. It is mainly prescribed for women with a family history of breast cancer or those with other risk factors. Like any medication, it has potential side effects, including hot flashes, leg cramps, and an increased risk of blood clots. Consulting a doctor before using Ralista 60 for breast cancer risk reduction is crucial to determine if the benefits outweigh the risks for an individual patient.